USPTO serial 78755195
PERFECTING THE SCIENCE OF GENE DELIVERY
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCDOWELL, MATTHEW J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PERFECTING THE SCIENCE OF GENE DELIVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eric S. Marzluf
Eric S. Marzluf Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.11th Floor - Seven Penn Center1635 Market StreetPhiladelphia, PA 19103-2212Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays and reagents for use in genetic research; Biochemicals namely, polypeptides for in vitro research use; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Cells for scientific, laboratory or medical research | ACTIVE | — |
| 005 | Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting compounds that facilitate delivery of a wide range of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of central nervous system disorders, cardiovascular, dermatological, diabetic, infectious, respiratory, and hormonal disease; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely, anticoagulants; Pharmaceutical preparations namely,antidepressants; Pharmaceutical preparations namely,appetite suppressants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, anti-infectives | ACTIVE | — |
| 042 | Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Pharmaceutical research services; Research and development of vaccines and medicines; Research on the subject of pharmaceuticals; Scientific research; Scientific research and development; Scientific research in the field of genetics and genetic engineering | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Lentigen Corporation
- Other trademarks owned by Lentigen Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PERFECTING THE SCIENCE OF GENE DELIVERY
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 2, 2009 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 2, 2009 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 6, 2008 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 5, 2008 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 23, 2008 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 23, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 12, 2008 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 25, 2008 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 25, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 14, 2007 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 24, 2007 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 24, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 17, 2007 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 17, 2007 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 16, 2007 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 16, 2007 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 16, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 12, 2007 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 12, 2007 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 12, 2007 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 12, 2007 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 25, 2006 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 2, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 12, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 13, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 3, 2006 | ALIE | ASSIGNED TO LIE | — |
| Feb 27, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 17, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 17, 2006 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 17, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 7, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 22, 2005 | NWAP | NEW APPLICATION ENTERED | — |